University of Miami Miami Valves 2025

1. Overview
The University of Miami Miami Valves 2025 is a premier structural heart disease conference focusing on the latest innovations in transcatheter valve therapies. The course provides a deep dive into TAVR, TMVR, and tricuspid interventions, alongside cutting-edge research on AI integration and novel device clinical trials.
Course Date: 2025
2. Learning Objectives

Evaluate recent clinical trial data for TAVR, including the PROPEL and EASY II trials.

Discuss the management of complex aortic valve cases, such as bicuspid anatomy and chronic aortic regurgitation.

Analyze emerging technologies for mitral valve repair and replacement, focusing on TEER durability and neo-LVOT simulation.

Review FDA-approved and investigational therapies for tricuspid regurgitation, including replacement and edge-to-edge repair.

Implement novel techniques for structural interventions, including PFO closure in older adults and management of paravalvular leaks.

3. Target Audience

Best for interventional cardiologists and cardiac surgeons who want updates on structural heart disease and transcatheter valve therapies.

4. Topics

What Did We Learn from TAVR UNLOAD

Selected Case of CE Approved TAVR Valve – Acurate Neo2

Hybrid TAVR

Septal Occulders- Not Just for the Intra-Atrial Septum

Novel Vascular Closure Device (xDot) – First in Human Experience

AI for Cardiovascular Staff Support

Novel RV Restoration System

Novel TMVR Devices

Latest Clinical Update – Silara MiBridge. Direct Annuloplasty System

Novel Transcatheter Mitral Annuloplasty Repair. Technology and Pre-Clinical Experience

EASY II Trial – Pioneering Temporary A-V Sequential Pacing for Enhanced Cardiac Care

Novel Device for Pulmonic Valve – Alterra

Tricuspid Valve Replacement in a Patient with a Torn Leaflet

Understanding the Tricuspid Regurgitation (Pathologist Perspective)

Multi Modality Imaging of Tricuspid Valve

Surgical Treatment of Tricuspid Valve

FDA Approved Edge to Edge Repair of Tricuspid (What We Know)

FDA Approved Tricuspid Valve Replacement – What We Know

TTVR with the Evoque Valve via the Transjugular Approach

Expanding Indications for PFO Closure Patients ≥ 60-Years Old

A Case of Severe Bioprosthetic Valve Dysfunction

Neo-LVOT Simulations for TMVR

Preventing LVOT Obstruction During TMVR – Septal Reduction and LAMPOON – What We Know

TMVR and the Tendyne Roll-In and MAC Experience

APOLLO Trial MAC Cohort

Investigational Transeptal TMVR – SAPIEN M3

ViMAC with SUPERMAN

Imaging to Plan Mitral Valve Procedures

Durability of Edge-to-Edge Repair

TEER in Moderate MR

Recurrent Heart Failure after M-TEER – More than the Mitral Valve

Clinical Trials for Mitral Regurgitation Beyond TEER – Where to Next

Progress in Mitral Valve Replacement

LAVA-ECMO for Cardiogenic Shock and Acute Aortic Regurgitation as a Bridge to Valve Replacement

Pathological Insights to the Native Aortic Valve Regurgitation

Dedicated TAVR Devices for Chronic Aortic Regurgitation

Single Center Results for a Balloon Expandable Valve in Native Valve AI

Where Are We with TAVR for Bicuspid

AI Simulation Assisted TAVR

A Case of Bicuspid TAVR with AI Planning

TAVR 2025 – The Begins….

TAVR US Origin

Clinical Trial Propel TAVR Forward – Building the Evidence Base for Low Surgical Risk Patients

Late PVL After BE THV

Transcatheter Management of Failed Ross Procedure

Short Term ACS Post TAVR

On the Shoulders of Our Mentors… How to Maximize Your Career Development Pathway

Left Atrium to Coronary Sinus Shunting – Edwards’ APTURE Shunt and ALT-FLOW II Trial

Transcatheter Treatment of a Sinus Venous ASD with Partial Anomalous Pulmonary Venous Return

Percutaneous Tricuspid Valve Intervention(s)

Percutaneous Stenting of Severe LVAD Outflow Graft Obstruction